Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM.
Jagannath
Sundar
S
St Vincent's Catholic Medical Center, 325 W. 15th Street, New York, NY 10011-8202, USA. sjagannath@aptiumoncology.com
Dimopoulos
Meletios A
MA
Lonial
Sagar
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D004357:Drug Synergism; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000187:drug effects
D000970:Antineoplastic Agents; D001897:Boronic Acids; D056572:Histone Deacetylase Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide